Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03839771
Title A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Ivosidenib

Enasidenib

Age Groups: adult | senior
Covered Countries FRA | ESP | DEU | BEL | AUT

Additional content available in CKB BOOST